Merck says experimental pill cuts worst effects of Covid-19

Merck amp Co said that its experimental Covid19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorise its useIf cleared Mercks drug would be the first pill shown to treat Covid19 a potentially major advance in efforts to fight the pandemic All Covid19 therapies now authorised in the US require an IV or injectionMerck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug called molnupiravir within five days of Covid19 symptoms had about half the rate of hospitalisation and death as patients who received a dummy pill The study tracked 775 adults with mildtomoderate Covid19 who were considered higher risk for severe disease due to health problems such as obesity diabetes or heart diseaseAmong patients taking molnupiravir 73 per cent were either hospitalised or died at the end of 30 days compared with 141 per cent of those getting the dummy pill There were no deaths in the drug group after that time period compared with eight deaths in the placebo group according to Merck The results were released by the company and have not been peer reviewed Merck said it plans to present them at a future medical meetingAn independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong Company executives said they are in discussions with the Food and Drug Administration and plan submit the data for review in coming daysIt exceeded what I thought the drug might be able to do in this clinical trial said Dr Dean Li vice president of Merck research When you see a 50 per cent reduction in hospitalization or death thats a substantial clinical impactAlso Read Zydus Cadilas ZyCoVD vaccine soon to be part of Indias inoculation drive CentreSide effects were reported by both groups in the Merck trial but they were slightly more common among the group that received a dummy pill The company did not specify the problems Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease The US has approved one antiviral drug remdesivir specifically for Covid19 and allowed emergency use of three antibody therapies that help the immune system fight the virus But all the drugs have to given by IV or injection at hospitals or medical clinics and supplies have been stretched by the latest surge of the delta variantThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever